2024年5月31日 · In this work we generated HIV Gag derived VLP exposing an RSV- or hMPV-F immunogen, directly fused to Gag, as a strategy to increase surface antigen density and induce better B-cell activation. Pre-fusion RSV-F conformation provides the best presentation of neutralizing epitopes [4], [6].

2018年5月15日 · VLP immunization of dams provides significant protection to pups from RSV challenge and reduced pulmonary inflammation. Collectively, our results show that a VLP vaccine with RSV F and G...

2024年7月18日 · LID/ΔM2-2/1030s（SP0125）是赛诺菲与美国国家过敏和传染病研究所（NIAID）合作开发的一款针对RSV感染的鼻喷减毒活疫苗，适用于全年龄段幼儿。 公开资料显示，LID/ΔM2-2/1030s可以在保护新生儿在第二个RSV流行季（次年4月-次年9月）不受感染。 目前，该疫苗已进入Ⅲ期临床。 赛诺菲预计最早将在2026年提交该疫苗的上市申请。 Icosavax /阿斯利康的IVX-A12是一种组合蛋白病毒样颗粒（VLP）疫苗，由IVX-121（Icosavax的RSV预融合F …

2024年3月19日 · The designed RBHcAg-based multiple-epitope-presenting VLP formulated with MF59-like adjuvant elicited a potent and balanced Th1/Th2 immune response, and offered substantial protection in mice ...

背景 病毒样颗粒 （VLP）疫苗病毒样颗粒（Virus-likeParticles，VLP）是由病毒的单个或多个 结构蛋白 自我组装形成的高度结构化蛋白颗粒。 由于 不含有病毒的遗传物质，VLP不能自主复制，不具备传染性，安全性较高。

RSV VLP vaccines were demonstrated to be unique in conferring protection against RSV while preventing vaccine-enhanced respiratory disease upon RSV infection [93,131]. These preclinical outcomes of RSV VLP vaccines in mice and cotton rat animal studies provide evidence warrantying further development of effective and safe RSV vaccines.

2020年8月19日 · To support anti-viral and vaccine development efforts, we developed an RSV virus-like particle (VLP) platform to explore the role RSV F and G protein interactions in disease pathogenesis. Since VLPs are immunogenic and a proven platform for licensed human vaccines, we also considered these VLPs as potential vaccine candidates.

2024年9月14日 · 据新闻稿，该重组呼吸道合胞病毒疫苗LYB005基于派诺生物自主搭建的通用型类病毒纳米颗粒(U-VLP™)技术平台研发，通过专有Covalink®技术与RSV重组抗原蛋白偶联形成嵌合U-VLP™抗原。

2017年12月2日 · The goal of this study was to assess the generation of protective immune responses in mice previously infected with RSV by virus-like particle (VLP) vaccine candidates containing a stabilized pre-fusion form of the RSV F protein or a stabilized post-fusion F protein.

LYB005是派诺生物基于U-VLP™技术平台研发，通过专有Covalink®技术与RSV重组预融合F抗原蛋白偶联形成嵌合RSV PreF VLP (Virus-Like Particle，类病毒颗粒)。差异性的抗原分子设计，能够诱导机体产生更强的免疫应答，并覆盖RSV-A和RSV-B两个亚组。